Kiniksa Pharmaceuticals (KNSA)

• Market cap: $3.56B
• 1 day: 1.57%
• 5 days: -1.48%
• 1 month: 2.47%
• 3 months: 12.4%
• 6 months: 30%
• Year to date: 10.69%
• 1 year: 102.44%
• 5 years: 103.15%
• 10 years: 138.83%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Employees: 366